Healthcare Industry News: immunotherapy
News Release - February 17, 2015
Regen BioPharma, Inc. Expands Management Team With the Addition of New CFO Todd CavenSAN DIEGO, CA--(Healthcare Sales & Marketing Network) - Regen BioPharma Inc. (OTC PINK: RGBP) announced that it has appointed Todd Caven to serve as the company's Chief Financial Officer. Mr. Caven is the cofounder of Saguaro Capital Partners, an Arizona based company that raises growth capital for medical device and technology companies throughout the United States., and Rock Ridge Enterprises LLC, a Minnesota-based Private Equity firm. Mr. Caven earned an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
Regen BioPharma's Chairman & CEO David Koos stated, "Mr. Caven is an accomplished executive with 30 years of experience in the areas of corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. We feel he will be a valuable addition to our management team and we look forward to his expected contributions to our future growth and business development."
The appointment of Mr. Caven is the second major hire made by the company since the beginning of 2015 following the appointment of Dr. Christine Ichim to the position of Director of Molecular Therapeutics.
ABOUT REGEN BIOPHARMA INC.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTC PINK: RGBP). The Company is focused on identifying undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia. Regen is majority owned by Bio-Matrix Scientific Group Inc. (OTC PINK: BMSN).
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Source: Regen BioPharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.